|
Dec 27
|
AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
|
|
Dec 27
|
Trending tickers: Intel | Tencent | RayzeBio | Astrazeneca
|
|
Dec 27
|
16 Most Promising Dividend Stocks According to Analysts
|
|
Dec 27
|
PRESS DIGEST-British Business - Dec 27
|
|
Dec 26
|
AstraZeneca to Acquire Gracell in $1.2 Billion Deal to Further Cell Therapy Goals
|
|
Dec 26
|
AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies
|
|
Dec 22
|
Ionis (IONS), AstraZeneca's Eplontersen Receives FDA Nod
|
|
Dec 22
|
Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate
|
|
Dec 22
|
These 3 Big Pharma Stocks Are Making Big Plays With AI
|
|
Dec 22
|
Ionis, Astrazeneca win FDA approval of competitor to Alnylam drug
|
|
Dec 22
|
WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
|
|
Dec 21
|
CORRECTED-UPDATE 2-US FDA approves Ionis-AstraZeneca's nerve disease drug
|
|
Dec 21
|
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
|
|
Dec 19
|
13 Most Promising Healthcare Stocks According to Analysts
|
|
Dec 19
|
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
|
|
Dec 19
|
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
|
|
Dec 18
|
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider
|
|
Dec 18
|
11 Best European Dividend Stocks to Buy
|
|
Dec 18
|
13 Most Profitable Pharmaceutical Stocks Now
|
|
Dec 10
|
AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?
|